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Abstract
Background: A Phase 1-2b study of the blood stage malaria vaccine AMA1-C1/Alhydrogel was conducted in 336
children in Donéguébougou and Bancoumana, Mali. In the Phase 2 portion of the study (n = 300), no impact on
parasite density or clinical malaria was seen; however, children who received the study vaccine had a higher
frequency of anaemia (defined as haemoglobin < 8.5 g/dL) compared to those who received the comparator
vaccine (Hiberix). This effect was one of many tested and was not significant after adjusting for multiple
comparisons.
Methods: To further investigate the possible impact of vaccination on anaemia, additional analyses were
conducted including patients from the Phase 1 portion of the study and controlling for baseline haemoglobin,
haemoglobin types S or C, alpha-thalassaemia, G6PD deficiency, and age. A multiplicative intensity model was
used, which generalizes Cox regression to allow for multiple events. Frailty effects for each subject were used to
account for correlation of multiple anaemia events within the same subject. Intensity rates were calculated with
reference to calendar time instead of time after randomization in order to account for staggered enrollment and
seasonal effects of malaria incidence. Associations of anaemia with anti-AMA1 antibody were further explored
using a similar analysis.
Results: A strong effect of vaccine on the incidence of anaemia (risk ratio [AMA1-C1 to comparator (Hiberix)]=
2.01, 95% confidence interval [1.26,3.20]) was demonstrated even after adjusting for baseline haemoglobin,
haemoglobinopathies, and age, and using more sophisticated statistical models. Anti-AMA1 antibody levels were
not associated with this effect.
Conclusions: While these additional analyses show a robust effect of vaccination on anaemia, this is an intensive
exploration of secondary results and should, therefore, be interpreted with caution. Possible mechanisms of the
apparent adverse effect on haemoglobin of vaccination with AMA1-C1/Alhydrogel and implications for blood stage
vaccine development are discussed. The potential impact on malaria-associated anaemia should be closely
evaluated in clinical trials of AMA1 and other blood stage vaccines in malaria-exposed populations.
Background
A vaccine against Plasmodium falciparum has long been
sought and is a badly needed tool in the fight to elimi-
nate and eradicate malaria. Experiments indicate that
parasites and clinical disease can be controlled through
passive transfer of antibody [1,2], although specific clini-
cal markers of protection have not yet been elucidated.
A partially protective pre-erythrocytic vaccine is cur-
rently in Phase 3 trials [3]. However, a “second genera-
tion” more highly protective vaccine is needed. Inclusion
of blood stage antigens in a multi-stage vaccine would
likely lead to higher levels of protection against clinical
disease, and would also provide protection against epi-
demic malaria if pre-erythrocytic immunity is incom-
plete [4].
AMA1 is one of the leading blood stage vaccine candi-
dates, and was evaluated in a Phase 1-2b trial in
malaria-exposed children in Mali [5,6]. This trial evalu-
ated a vaccine combining two allelic forms of AMA1
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was moderately immunogenic and no overall impact of
vaccination on malaria parasitaemia or disease was seen
[6]. Allele-specific effects were not demonstrated [7]. As
per the analytic plan for the Phase 2 (biologic impact)
part of the study, 16 secondary outcomes were exam-
ined for data up to day 154. Four of the 16 secondary
outcomes examined were related to haemoglobin (Hb);
all showed trends towards a negative impact of vaccina-
tion with AMA1 relative to the comparator group, with
two of these statistically significant at the 0.05 level
(mean Hb during clinical malaria, unadjusted p = 0.004,
and number of episodes with Hb < 8.5 g/dL, unadjusted
p = 0.029), although differences were no longer signifi-
cant after correction for multiple tests. Additional ana-
lyses using all subjects with available data from day 1
u n t i ld a y3 6 4s h o w e ds i g n i f i c a n c eo fH be f f e c t s :b o t h
minimum Hb [p = 0.0121] and mean Hb during clinical
malaria events [p = 0.0044] were significantly lower in
t h eA M A 1g r o u p ,a n dt h ei n c i d e n c eo fH b<8 . 5g / d L
[p = 0.0096] was more frequent in the AMA1 group. An
extended follow-up period from November/December
2007 until January 2008 was added due to concern
about the possible impact on anaemia events, and an
imbalance in serious adverse events related to malaria.
However, no significant differences in Hb endpoints
were found using only the extended follow-up data [6].
This paper describes further analyses of the differences
between the AMA1-C1 va c c i n ea n dt h ec o n t r o l
(Hiberix) groups in the study described in [6]. Addi-
tional analyses focused on the repeated incidence of
anaemia and explored possible confounders or mechan-
isms of action of the effect of vaccination on Hb. Vari-
ables included were: baseline Hb, as lower Hb at the
start of the malaria transmission season has been shown
to be associated with anaemia during clinical malaria
[8]; Hb S, C, and alpha-thalassaemia, as variant Hb is
known to be protective against severe malaria and Hb S
has been shown to delay time to first clinical malaria
event [9-12], and these variables could also affect the
risk of anaemia. Similarly, G6PD status is a potential
confounder for anaemia [13] and was included in the
model. Age is a risk factor for development of anaemia,
with younger children more vulnerable [14], therefore
age was added. Data on 24 subjects from the Phase 1
part of the study was also included (see [5]).
Methods
Description of study
The trial was conducted under a clinical protocol
reviewed by the Institutional Review Board of NIAID/
NIH, and by the Ethics Committee of the University of
Bamako, Faculty of Medicine, Pharmacy, and Odonto-
Stomatology. Details on the study design and results of
primary and secondary outcomes have been published
[5,6]. Briefly, in the dose-escalating Phase 1 part of the
study, 36 2-3 year old children were randomized 1:1:1 to
receive 20 μg AMA1-C1/Alhydrogel, 80 μgA M A 1 - C 1 /
Alhydrogel, or the comparator vaccine (Hiberix, Hemo-
philus influenza B), with two doses given at a four-week
interval. In the Phase 2 part of the study, 300 children
were randomized 1:1 to receive either 80 μg AMA1-C1/
Alhydrogel or the comparator. Children were followed
both actively and passively to study day 154, with para-
site density (by malaria smears) and haemoglobin (by
Hemocue) measured monthly and at sick visits through
the malaria transmission season. Hb was also measured
as part of complete blood counts at several time points
during the study. Any time two measurements of Hb
were done on the same day for the same subject, the
minimum of the two was taken for the response.
Screening Hb < 8.5 g/dL was an exclusion criterion,
although a few children had baseline Hb lower than this
on the day of enrollment since results of Hb were not
known prior to vaccination on Day 0.
Anti-AMA1 antibody levels were determined using a
standardized ELISA as previously described [15]. Hb
and alpha-thalassaemia typing, and G6PD deficiency
were determined as previously described [13] from spe-
cimens obtained at the start of the second transmission
season, when children in the study were re-enrolled for
additional follow up.
Statistical methods
Data selection
As this was a safety analysis, all children with data avail-
able from the Phase 1 and Phase 2 studies were
included in the analysis (intent to treat), except that
children in the Phase 1 part of the study who received
the low dose (20 μg AMA1-C1) were excluded. Addi-
tionally, children missing all Hb values after baseline,
and children missing Hb type, alpha-thalassaemia, or
G6PD were excluded from the primary analysis. For the
primary analysis only the first 154 days for each subject
were included, since that was the period of intensive fol-
low-up during which Hb was measured frequently.
Primary model
The primary analysis was an Anderson-Gill-type multi-
plicative intensity model on the anaemia (Hb < 8.5 g/dL)
incidence [16]. This model is similar to a Poisson model
on the rate of anaemia, but has several enhancements.
First, it is a time to event analysis (similar to Cox regres-
sion but allowing multiple events), so that it adjusts for
the malaria season by allowing different intensity func-
tion (analogous to the hazard function in Cox regression)
at each calendar time at risk. Modeling the “baseline”
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z a t i o n ,a si su s u a l l yd o n e ,i sp r e f e r a b l ef o rt h e s ed a t a
because children entered the study in a staggered fashion
through the early malaria transmission season and there
is a strong seasonal effect on malaria in Mali. A further
enhancement is that a random effect (i.e., a frailty effect)
is added for each subject in order to adjust for correlation
of events within a subject. The gamma distribution was
used to model this variability of the subjects’ intensity
rates (i.e., to model the frailty) (see [16], section 9.5).
Baseline Hb is an important covariate in the frequency
of anaemia in this population [8]. Standard methods
either use a categorical expression of this variable (e.g.,
2 groups: Hb < 10 or Hb > = 10) or treat it as continu-
ous. Here the functional form for this covariate was
examined by fitting two separate Poisson models on
anaemia incidence rate using all the other covariates
within each vaccine arm. The models included effects
for sex, age at baseline (treated as a continuous vari-
able), G6PD deficiency (which is binary, equal to 1 for
hemizygous males and homozygous females and 0 for
all others, because heterozygous females are not
expected to have a strong effect), HbS (equals 1 for Hb
type = AS or SC, 0 otherwise), HbC (equals 1 for Hb
type = AC or SC, 0 otherwise), and alpha-thalassaemia
(categorical variable with 2 degrees of freedom, repre-
senting the three classes: wild-type, heterozygous, and
homozygous). There were no individuals with the CC or
SS phenotype; individuals with the SC phenotype contri-
bute to both the HbS and HbC variable. Residuals were
then plotted against baseline Hb and a nonparametric
regression was used to plot the functional form. Resi-
duals from the Poisson rate model were used since it is
not straightforward how to derive a single residual per
subject from the multiplicative intensity model, and the
Poisson model should give a similar functional form. An
offset for the number of days at risk was used in the
Poisson regression, calculated for each subject using the
number of days from entering the study until the last
Hb measurement was taken. The offset is the standard
way that rates are modelled using Poisson regression,
allowing us to correctly account for the Poisson-like var-
iance of the counts, while modelling relative risks in
terms of the rates not the counts (see for example, [17]).
In the residual plot from these models, a nonparametric
smoother was then used (the lowess function in R using
the default span, [18]) to try and see the functional form
that baseline Hb had on the rate of anaemia. From these
residual plots, a simple functional form for baseline Hb
was defined to be included in all subsequent models.
A multiplicative intensity model was then run to see if
there was an effect of vaccine group after controlling for
baseline Hb as described, as well as the other covariates
(sex, age, G6PD, HbS, HbC, alpha-thalassaemia).
Additional analyses
The relationship of vaccine to maximum severity of
anaemia adverse events was evaluated using exact Wil-
coxon-Mann-Whitney (WMW) tests, where the adverse
events were graded according to the age at which they
occurred, and aged-stratified grading scales were based
on data from previous studies in children in Mali [8]
(Table 1). Since the primary analysis continued to show
a vaccine effect on anaemia rate, the relationship
between minimum Hb and antibody levels at day 42
was explored. The lowess smoother was used in a man-
ner similar to that described above for Figure 1. To test
for relationships in non-ordered variables (e.g., Hb type),
Fisher’s exact test was used. To see if the anaemia
effects were substantially driven by unscheduled or sick
visits, separate analyses were performed using only
scheduled or unscheduled visits. Analyses were done in
R (version 2.11.1) using the survival package (version
2.35-8) for the primary analysis and the coin package
(version 1.0-11) for the exact WMW tests [19].
Results
Description of subjects for primary analysis
Two (2) children withdrew from the study immediately
after first vaccination and, therefore, did not have any
Hb measurements other than baseline, and were not
included. Of the remaining 322 children who received
either 80 μg AMA1-C1 or the comparator (161 in each
group), Hb type was obtained for 276 (134 who
received the study vaccine and 142 who received the
comparator), and alpha-thalassaemia and G6PD status
were obtained for 275 children (134 who received the
study vaccine and 141 who received the comparator).
For the primary analysis, data were available for 133
subjects who received the study vaccine (12 in Phase 1,
121 in Phase 2), and 141 who received the comparator
(11 in Phase 1, 130 in Phase 2). The primary data had
a fairly even distribution of the Hb types (Fisher’s
exact test, p = 0.586), and of the G6PD status (Fisher’s
exact test p = 0.420), but alpha-thalassaemia was less
evenly distributed (Fisher’s exact test p = 0.040) (see
Tables 2, 3, and 4).
Baseline Hb was similar in the two groups (AMA1
group mean = 10.47, comparator mean = 10.35, t-test
p = 0.311); however, when baseline Hb was examined in
Table 1 Grading scale for haemoglobin related adverse
events (based on data from Dicko, Klion et al [8])
Age Normal Grade 1 Grade 2 Grade 3 Grade 4
1-2 years old 9-10.5 8.0-8.9 7.0-7.9 6.0-6.9 <6.0
3 years old 10.0-11.5 9.0-9.9 8.0-8.9 7.0-7.9 <7.0
4 years old 10.5-11.5 9.4-10.4 8.3-9.3 7.0-8.2 <7.0
All values are g/dL.
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age-stratified grading scales, an uneven distribution of
anaemia events in the groups at baseline was seen (see
Table 5, Exact Wilcoxon-Mann-Whitney test p = 0.002).
There were significantly higher grade anaemia events by
this scale in the comparator (Hiberix) group than in the
AMA1-C1 group at baseline.
Primary analysis
Residuals for Hb are shown in Figure 1. From this fig-
ure, two new variables were created that act on the
anaemia incidence rate: one variable represents a linear
function for baseline Hb < 10 and a second variable
represents a possibly different linear function for base-
line Hb > = 10.
The results of the multiplicative intensity model are
g i v e ni nT a b l e6 .T h eA M A 1 - C 1g r o u ph a dar i s ko f
anaemia twice that of the comparator vaccine, with a risk
ratio of 2.01 (95% Confidence Interval 1.26, 3.20, p =
0.0035). The other significant effects were for subjects
with baseline hg < 10, with each g/dL below 10 increasing
t h er i s ko fs u b s e q u e n ta n a e m i ab yaf a c t o ro f4 . 2 6( 9 5 %
CI 2.72, 6.69; p < 0.0001), consistent with previous results
in Mali [8], and age at time of anaemia event, with the
risk ratio reduced by a factor of 0.45 for each year older
(95% CI 0.29, 0.70; p = 0.0004).
Modifications to primary analysis
Since the additional added variables (sex, Hb type, and
G6PD status) did not appear to be important, a simpler
model without the non-significant variables was also
used, enabling the inclusion of more subjects (161 in
each vaccine group). A similar estimate of the risk ratio
was obtained for AMA1-C1 group: Risk Ratio = 1.71,
95% CI 1.09, 2.66, p = 0.019. A simpler Poisson model,
still including all the variables in Table 6 (and conse-
quently using the same set of subjects as in the primary
analysis) also gave similar results (rate ratio 2.22, 95%
CI 1.45, 3.40; p = 0.0003).
Since vaccination with AMA1-C1 had a significant
effect on the level of anti-AMA1 antibody (see Figure
three in Ref [6], antibody levels were examined for a
possible relationship to anaemia incidence. The vaccine
was given at days 0 and 28 and had peak values of anti-
AMA1 ELISA values at vaccine day 42. Using the pri-
mary analysis described above, except only including
anaemia events occurring between day 42 and day 154
(rather than between day 0 and day 154), an effect of
vaccine was still seen (RR = 2.09, p = 0.010). Using the
same data set, the variable for vaccine group was
replaced with the average of the 3D7 and FVO anti-
AMA1 antibody levels within each subject at day 42. If
the effect of the vaccine was mediated through the level
of antibody, this would be expected to be a significant
effect; however, no effect was seen (HR for an increase
in day 42 antibody by 1000 ELISA units = 0.96, 95% CI
[0.84, 1.10], p = 0.59). Similarly, no significant effect of
day 42 antibody was seen when separate analyses were
Table 2 Frequency of hemoglobin variants and G6PD
deficiency in subjects in primary analysis - Haemoglobin
types
Vaccine received AC AS SC AA
AMA1-C1 12 18 2 101
Hiberix 16 18 0 107
AC = heterozygous for hemoglobin C, AS = sickle trait, SC = hemoglobins S
and C, AA = wild type.
Table 3 Frequency of hemoglobin variants and G6PD
deficiency in subjects in primary analysis - Alpha-
thalassaemia
Vaccine received HE HO WT
AMA1-C1 34 10 89
Hiberix 35 2 104
HE = heterozygous, HO = homozygous, WT = wild type.
Table 4 Frequency of hemoglobin variants and G6PD
deficiency in subjects in primary analysis - G6PD
Vaccine received A- A-/- A* A+
AMA1-C1 6 3 4 120
Hiberix 3 1 7 130
A- = hemizygous males, A-/-homozygous females, A* = heterozygous females,
A+ = wild type.
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Figure 1 Plot of Residual from Poisson Regression.L i n e sa r e
lowess smooths and motivate the functional form of the effect of
baseline Hgb on the incidence rate of Hb < 8.5.
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transformed antibody units were used. To see the lack
of effect in a different manner, in Figure 2 the average
day 42 anti-AMA1 antibody by minimum Hb for both
vaccine groups was plotted and nonparametric fits were
drawn. No obvious relationship of anti-AMA1 antibody
to minimum Hb was observed; although there is an
apparent trend for higher day 42 anti-AMA1 antibody
to lead to lower minimum Hb in the Hiberix group, this
effect is not significant (p = 0.209 by linear regression
on log transformed antibody values). A similar plot for
the change in anti-AMA1 antibody (day 42-day 0) also
showed no effects (Figure 3).
Additional analyses
Table 7 shows the maximum severity anaemia adverse
events occurring after vaccination in the AMA1-C1 and
comparator groups. Higher grade anaemia events
occurred in the AMA1 group, with borderline signifi-
cance of this effect (exact Wilcoxon-Mann-Whitney p =
0.051). Finally, to see if the anaemia effects seen were
manifested primarily during the unscheduled visits, the
primary analysis was repeated twice more, first using
only Hb measured on scheduled visits and then using
only Hb measured at sick or unscheduled visits (pre-
sumably often due to malaria). Both results were similar
to the primary analysis (RR [AMA1-C1 to comparator]
from scheduled = 2.10 and from unscheduled = 2.24).
Discussion
This intensive exploration of the relationship of AMA1
vaccine with anaemia was motivated by secondary
results uncorrected for multiple comparisons, so results
should be interpreted not as a confirmatory study but as
the continuation of an exploratory study. Nevertheless,
despite these cautions on over-interpretation, effects
Table 5 Anaemia events at baseline, according to age-
stratified grading scale (see Table 1)
AMA1-C1 Hiberix
Grade 0 120 107
Grade 1 11 29
Grade 2 2 5
Table 6 Results of Primary Multiplicative Incidence Model
on Risk of Hg < 8.5 g/dL
Variable Risk Ratio Two-sided p-value
(95% CI) (NS > 0.25)
Vaccination with 80ug 2.01 (1.26, 3.20) 0.0035
AMA1-C1
Age at time of anaemia event* 0.45 (0.29, 0.70) 0.0004
Baseline Hg > = 10 g/dL 0.78 (0.52, 1.17) NS
Baseline Hg < 10 g/dL 4.26 (2.72, 6.69) <0.0001
Male Sex 0.74 (0.46, 1.17) NS
HbS 0.83 (0.42, 1.61) NS
HbC 0.96 (0.43, 2.15) NS
G6PD deficiency 2.27 (0.85, 6.04) NS
a-thalassaemia heterozygote 0.71 (0.41, 1.23) NS
a-thalassaemia homozygote 0.41 (0.12, 1.45) NS
*Risk ratio is reduced by a factor of 0.452 for each year older.
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Hb for AMA1 and comparator groups, with nonparametric fits.
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Figure 3 Day 42-Day 0 anti-AMA1 antibody plotted against
minimum Hb for AMA1 and comparator groups, with
nonparametric fits.
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Page 5 of 7were still seen when more subjects were included, more
potentially confounding variables were included, and
more statistically sophisticated analyses were performed.
The strengthening of the effect after inclusion of base-
line haemoglobin may be because of the uneven rando-
mization at baseline, i.e. children enrolled in the
comparator group had lower baseline haemoglobin and
more anaemia, thus partially masking the strength of
the association of vaccination of AMA1 and anaemia in
the initial analysis. The imbalance in anaemia was seen
in higher grade as well as lower grade events, although
numbers were small and this difference was not statisti-
cally significant. Clearly the possible impact on anaemia
should be closely evaluated in future clinical trials of
AMA1 in malaria-exposed populations.
In theorizing about the possible causes of this appar-
ent anaemia effect, the first possibility that should be
considered is that the comparator Hemophilus influenza
B vaccine (Hiberix) was somehow protective against
anaemia, perhaps through a general improvement in
health status. However, this vaccine primarily protects
against invasive Hib disease in the first year of life, and
a l s ow o u l db ee x p e c t e dt oe x e r tal e v e lo fh e r di m m u -
nity to non-vaccinated children in the village [20]. No
previous studies of this class of vaccines which showed
protection from anaemia were found in a literature
search, and a protective effect of Hiberix is unlikely.
If the increase in anaemia in the group receiving the
AMA1 vaccine is a true effect of vaccination, what pos-
sible mechanisms could explain this? Experimental falci-
parum challenge studies in Aotus monkeys have shown
profound anaemia in some cases, and partial control of
infection resulting in persistent low grade infection has
been postulated to be a possible mechanism for this
effect [21]. In the Phase 2 trial parasite densities were
similar between the vaccinated and control groups, and
time to first event (malaria infection, and fever at vary-
ing levels of parasitaemia) was similar between the
groups. Thus partial control of parasitaemia appears to
be an unlikely explanation in this case.
The aetiology of malaria anaemia is not well under-
stood [22,23]. Three mechanisms are thought to interact
to cause anaemia: lysis of infected and uninfected red
blood cells primarily during acute infection, sequestra-
tion (also occurring during acute infection), and bone
marrow suppression. The nadir in haemoglobin typically
occurs 4-5 days after treatment, and recovery from
anaemia can be prolonged. No difference in clinical evi-
dence of haemolysis (such as jaundice or splenomegaly)
was seen between the groups in this study, although
these were not study endpoints and it is possible that a
difference occurred but was not detected. Coombs tests,
haptoglobin, and reticulocyte counts were not done.
Sequestration is mediated by adherence factors, possibly
related to antibody. No association was seen here
between peak (day 42) or induced (day 42-day 0) anti-
AMA1 antibody levels and minimum hemoglobin.
Although there is no evidence showing a qualitative dif-
ference in vaccine-induced anti-AMA1 antibody com-
pared to the infection-induced antibody judged by
surface plasmon resonance technique or in vitro growth
inhibition assay (unpublished observation), there may be
some qualitative difference which these assays are not
able to detect, possibly contributing to increased lysis or
adherence. Pro-inflammatory cytokines are also thought
to play a role in malaria anaemia, with excessive produc-
tion of Th1 cytokines thought to be beneficial during
the early stages of a plasmodial infection and Th2 cyto-
kines likely to be protective in chronic infection or in
the recovery period [24,25]. The alum adjuvant used in
this vaccine induces a Th2 biased response, and it is
theoretically possible that when given with a blood stage
antigen the immune response is adversely shifted,
although how this would act remotely from the time of
vaccination is not clear.
Other efficacy field trials have been conducted with
blood stage vaccines. A Phase 2b trial in Kenyan chil-
dren of FMP1 (MSP1) adjuvanted with AS02 showed no
overall protection despite high levels of induced anti-
b o d y[ 2 6 ] .A ni m b a l a n c ew a ss e e ni nt h en u m b e ro f
cases of transient low haemoglobin (9 in 200 vaccinees
vs. 2 in 200 controls) but no significant difference in the
risk of Hb < 8.0 g/dL was seen and time to first episode
of Hb < 8.0 did not differ between the groups, although
there was a trend towards an increase in the vaccine
group (Hazard ratio 1.53 (95% CI 0.90, 2.59, p = 0.11).
Results of a Phase2b trial in Malian children of FMP2
(AMA1) adjuvanted with AS02 also showed no overall
protection despite high levels of antibody, although
strain specific effects were seen in the first year (5
th
Multilateral Initiative on Malaria, November, 2009; and
2009 annual meeting of the American Society of Tropi-
cal Medicine and Hygiene). No imbalance in anaemia
was seen, although these results are not yet published
and additional analysis is pending. A Phase 2b trial in
Malian children of MSP3 adjuvanted with alum is
ongoing (ClinicalTrials.gov Identifier: NCT00652275),
Table 7 Maximum Anaemia Adverse Event Grade at any
time after vaccination
Severity AMA1-C1 (n = 161) Hiberix (n = 161)
n % (95% CI) n % (95% CI)
Grade 0 32 19.9 (14.0-26.9) 40 24.8 (18.4-32.3)
Grade 1 50 31.1 (24.0-38.8) 58 36.0 (28.6-44.0)
Grade 2 48 29.8 (22.9-37.5) 43 26.7 (20.1-34.2)
Grade 3 24 14.9 (9.8-21.4) 17 10.6 (6.3-16.4)
Grade 4 7 4.3 (1.8-8.8) 3 1.9 (0.4-5.3)
Ellis et al. Malaria Journal 2011, 10:13
http://www.malariajournal.com/content/10/1/13
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also adjuvanted with alum is planned (5
th MIM Pan-
African Malaria Conference, 2009, Symposium 14).
While it is possible that the association of anaemia
with vaccination with AMA1-C1/Alhydrogel in this
study is an artifact, and no mechanism is apparent, the
robustness of these findings and the imbalance in anae-
mia seen in one other field trial of a blood stage vaccine
[26] are cause for concern. The impact of vaccination
on anaemia outcomes should be closely examined, parti-
cularly for field trials of blood stage vaccines in malaria-
exposed children.
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